Latest Breaking News On - David borah - Page 5 : comparemela.com

Bicycle Therapeutics plc: Bayer and Bicycle Therapeutics Enter Strategic Collaboration for Development of Novel Targeted Radionuclide Therapies in Oncology

Collaboration will leverage Bicycle Therapeutic's synthetic peptides for the discovery and development of multiple targeted radioconjugates of the company in oncology Advancing the use of

United kingdomLisa hennigDavid borahSarah suttonChristian rommelKevin leeExchange commissionPharmaceuticals divisionGlobal head of researchCapital markets corporate communicationsMember of the executive committeeUk national securityBicycle therapeuticBicycle therapeuticsGlobal headExecutive committee

Bicycle Therapeutics plc: Bicycle Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

Continued progress across pipeline, including encouraging BT8009 Phase I dose escalation results presented in Q1'23 Entered into a strategic collaboration with Novartis and expanded separate collaboration

United statesUnited kingdomDavid borahJennifer perrySarah suttonKevin leeLeadership teamDrug administrationExchange commissionAmerican society for clinical oncologyGerman cancer research centerCapital markets corporate communicationsDivision of radiopharmaceutical chemistryRadiopharmaceutical chemistryChief executive officerMultiple strategic collaborations

Bicycle Therapeutics plc: Bicycle Therapeutics Announces Collaboration With the German Cancer Research Center, to Discover and Develop Wholly Owned Bicycle Radio Conjugates for a Range of Oncology Targets

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced

Baden wübergUnited kingdomKevin leeMatthias ederSarah suttonDavid borahExchange commissionCapital markets corporate communicationsGerman cancer research centerCancer information serviceUniversity of heidelbergGerman cancer research center deutsches krebsforschungszentrumBicycle therapeuticsCancer researchChief executive officerBicycle toxin conjugates

Bicycle Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

Bicycle Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomKevin leeJennifer perryDavid borahSarah suttonGerman cancer research centerCapital markets corporate communicationsAmerican society for clinical oncologyExchange commissionLeadership teamDrug administrationDivision of radiopharmaceutical chemistryRadiopharmaceutical chemistryChief executive officerMultiple strategic collaborations

Bicycle Therapeutics plc: Bicycle Therapeutics to Present at the 2023 AACR Annual Meeting

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, today announced

United kingdomUnited statesDavid borahFay dufortThomasr jeffry evansSarah suttonLukas stanczukUniversity of glasgowAmerican association for cancer researchSchool of cancer sciencesCapital markets corporate communicationsBicycle therapeuticsCancer researchAnnual meetingPresentation detailsImmunomodulatory agents